Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval

This historic approval of the world’s first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL’s promise to develop and deliver innovations when there is a public health need
First marketing approval milestone for CSL and Arcturus Therapeutics since closing the Global Collaboration and Licensing agreement in 2022
With the approval of ARCT-154, CSL now offers an even more comprehensive portfolio of innovative vaccines that combat respiratory viral diseases.
KING OF PRUSSIA, Pa. and SAN DIEGO, Nov. 27, 2023 /PRNewswire/ — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.